| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Southern California Islet Cell Resources Center (T.M., K.F., I.T., C.V.S., F.K., Y.M.), Department of Diabetes, Endocrinology and Metabolism, City of Hope National Medical Center/Beckman Research Institute, Duarte, California 91010; Department of Surgery (T.M., C.V.S., Y.M.), University of California at Los Angeles, Los Angeles, California 90095; and Department of Gastroenterological Surgery (Y.K.), Graduate School of Medical Sciences, Kobe University, Kobe 650-0017, Japan
Address all correspondence and requests for reprints to: Yoko Mullen, M.D., Ph.D., Southern California Islet Cell Resources Center, Department of Diabetes, Endocrinology and Metabolism, City of Hope National Medical Center/Beckman Research Institute, 1500 East Duarte Road, Duarte, California 91010. E-mail: ymullen{at}coh.org.
Silymarin is a polyphenolic flavonoid that has a strong antioxidant activity and exhibits anticarcinogenic, antiinflammatory, and cytoprotective effects. Although its hepatoprotective effect has been well documented, the effect of silymarin on pancreatic ß-cells is largely unknown. In this study, the effect of silymarin on IL-1ß and/or interferon (IFN)-
-induced ß-cell damage was investigated using RINm5F cells and human islets. IL-1ß and/or IFN-
induced cell death in a time-dependent manner in RINm5F cells. The time-dependent increase in cytokine-induced cell death appeared to correlate with the time-dependent nitric oxide (NO) production. Silymarin dose-dependently inhibited both cytokine-induced NO production and cell death in RINm5F cells. Treatment of human islets with a combination of IL-1ß and IFN-
(IL-1ß+IFN-
), for 48 h and 5 d, resulted in an increase of NO production and the impairment of glucose-stimulated insulin secretion, respectively. Silymarin prevented IL-1ß+IFN-
-induced NO production and ß-cell dysfunction in human islets. These cytoprotective effects of silymarin appeared to be mediated through the suppression of c-Jun NH2-terminal kinase and Janus kinase/signal transducer and activator of transcription pathways. Our data show a direct cytoprotective effect of silymarin in pancreatic ß-cells and suggest that silymarin may be therapeutically beneficial for type 1 diabetes.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |